NI200800216A - Uso de compuestos peptídicos de tpo y composiciones farmacéuticas en el tratamiento de la anemia - Google Patents

Uso de compuestos peptídicos de tpo y composiciones farmacéuticas en el tratamiento de la anemia

Info

Publication number
NI200800216A
NI200800216A NI200800216A NI200800216A NI200800216A NI 200800216 A NI200800216 A NI 200800216A NI 200800216 A NI200800216 A NI 200800216A NI 200800216 A NI200800216 A NI 200800216A NI 200800216 A NI200800216 A NI 200800216A
Authority
NI
Nicaragua
Prior art keywords
tpo
pharmaceutical compositions
anemia
treatment
peptidic compounds
Prior art date
Application number
NI200800216A
Other languages
English (en)
Inventor
R Macdonald Brian
J Yurkow Edward
K Weis Jeffery
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NI200800216A publication Critical patent/NI200800216A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/196—Thrombopoietin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describe un método para tratar la anemia. El método incluye administrar un compuesto peptídico de TPO a un sujeto. También se describen composiciones farmacéuticas que incluyen un compuesto peptídico de TPO y un portador farmacéuticamente aceptable, así como métodos diagnósticos que emplean un compuesto peptídico de TPO autorizado.
NI200800216A 2006-02-14 2008-08-13 Uso de compuestos peptídicos de tpo y composiciones farmacéuticas en el tratamiento de la anemia NI200800216A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2006/005322 WO2007094781A1 (en) 2006-02-14 2006-02-14 Use of tpo peptide compounds and pharmaceutical compositions in the treatment of anemia

Publications (1)

Publication Number Publication Date
NI200800216A true NI200800216A (es) 2012-01-24

Family

ID=37904365

Family Applications (1)

Application Number Title Priority Date Filing Date
NI200800216A NI200800216A (es) 2006-02-14 2008-08-13 Uso de compuestos peptídicos de tpo y composiciones farmacéuticas en el tratamiento de la anemia

Country Status (19)

Country Link
EP (1) EP1984014B1 (es)
JP (1) JP2009526841A (es)
CN (1) CN101374540B (es)
AU (1) AU2006338308B2 (es)
BR (1) BRPI0621347B8 (es)
CA (1) CA2642389C (es)
CY (1) CY1115629T1 (es)
DK (1) DK1984014T3 (es)
EA (1) EA015562B1 (es)
ES (1) ES2516649T3 (es)
HK (2) HK1125055A1 (es)
IL (1) IL193268A (es)
NI (1) NI200800216A (es)
NO (1) NO341872B1 (es)
NZ (1) NZ570124A (es)
PL (1) PL1984014T3 (es)
PT (1) PT1984014E (es)
SI (1) SI1984014T1 (es)
WO (1) WO2007094781A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009256465B2 (en) * 2008-06-03 2015-05-14 Janssen Pharmaceutica Nv TPO mimetic peptide for preventing hematological disorder associated with cancer treatment
JP6150374B2 (ja) * 2012-11-15 2017-06-21 国立大学法人弘前大学 放射線被ばく治療剤及び放射線被ばく治療方法
US20200164039A1 (en) 2017-07-26 2020-05-28 Janssen Pharmaceutica Nv Methods of protecting vascular integrity induced by targeted radiation therapy
JP2022519196A (ja) 2019-01-25 2022-03-22 ヤンセン ファーマシューティカ エヌ．ベー． 全身照射／化学曝露に対する応答において臓器および血管損傷、造血回復ならびに生存に対する保護を増強する方法
KR20210120037A (ko) 2019-01-25 2021-10-06 잔센파마슈티카엔.브이. 수포제 및 가성 가스의 독성 영향 경감 방법
AU2020211412A1 (en) 2019-01-25 2021-08-12 Janssen Pharmaceutica Nv Methods for mitigating liver injury and promoting liver hypertrophy, regeneration and cell engraftment in conjunction with radiation and/or radiomimetic treatments
WO2023056444A1 (en) 2021-10-01 2023-04-06 Janssen Pharmaceutica N.V. Methods of increasing progenitor cell production
WO2024095178A1 (en) 2022-11-01 2024-05-10 Janssen Pharmaceutica Nv Thrombopoietin mimetic for use in the treatment of acute liver failure

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1843595A (en) * 1994-02-14 1995-08-29 University Of Washington Methods for stimulating erythropoiesis using thrombopoietin
MXPA05003057A (es) * 2002-09-18 2006-04-18 Johnson & Johnson Metodos para aumentar la produccion de celulas madre hematopoyeticas y plaquetas.
SG131110A1 (en) * 2003-08-28 2007-04-26 Ortho Mcneil Pharm Inc Peptides and compounds that bind to thrombopoietin receptors

Also Published As

Publication number Publication date
NZ570124A (en) 2011-05-27
HK1129571A1 (en) 2009-12-04
EA200870261A1 (ru) 2009-02-27
CY1115629T1 (el) 2017-01-04
WO2007094781A1 (en) 2007-08-23
CN101374540B (zh) 2013-03-06
NO341872B1 (no) 2018-02-12
IL193268A (en) 2015-02-26
EA015562B1 (ru) 2011-08-30
HK1125055A1 (en) 2009-07-31
EP1984014B1 (en) 2014-08-06
EP1984014A1 (en) 2008-10-29
PL1984014T3 (pl) 2015-02-27
CN101374540A (zh) 2009-02-25
AU2006338308A1 (en) 2007-08-23
CA2642389C (en) 2014-05-06
ES2516649T3 (es) 2014-10-31
NO20083928L (no) 2008-09-15
BRPI0621347B8 (pt) 2021-05-25
PT1984014E (pt) 2014-11-13
DK1984014T3 (da) 2014-09-15
SI1984014T1 (sl) 2014-12-31
CA2642389A1 (en) 2007-08-23
BRPI0621347A2 (pt) 2011-12-06
AU2006338308B2 (en) 2012-11-01
IL193268A0 (en) 2009-02-11
JP2009526841A (ja) 2009-07-23
BRPI0621347B1 (pt) 2018-05-08

Similar Documents

Publication Publication Date Title
NI200800216A (es) Uso de compuestos peptídicos de tpo y composiciones farmacéuticas en el tratamiento de la anemia
CO6761350A2 (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis
CL2008001374A1 (es) Compuestos derivados de pirazolo pirimidinas, inhibidores de pde9; composicion farmaceutica que comprende a dichos compuetos; utiles en el tratamiento de un trastorno neurodegenerativo y cognitivo tal como la enfermedad de alzheimer y esquizofrenia.
CL2008001274A1 (es) Compuestos macrolidos derivados de 5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahidrociclopropan[e]pirrolo[1,2-a][1,4]diazaciclopentadecinilo, inhibidores de la actividad de la proteasa ns3-ns4; su procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios y procedimiento de preparacion; y uso en el tratamiento de.....
AR047928A1 (es) Derivados de tetrahidropiridoindol
HN2008001720A (es) Arilimidazolonas y ariltriazolonas sustituidas como inihibidores de receptores de vasopresina
BRPI0720551A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, e, uso do mesmo, método para o tratamento de câncer, processos para a preparação de uma composição farmacêutica e de um composto ou de um sal farmaceuticamente aceitável do mesmo
CL2007001435A1 (es) Compuestos derivados de fenilalanina; proceso de prepatacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto como inhibidores de integrina para el tratamiento del cancer.
CR8919A (es) Analogos de tetrapeptidos
CL2008001721A1 (es) Compuestos derivados de 17-beta-ciano-18 alfa-homo-19-nor-androst-4-eno; que presentan actividad gestagena y antimineralcorticoide; composicion farmaceutica; y uso en el tratamiento de trastornos pre-peri-y posmenopausicos y trastornos premenstruales.
CL2007002167A1 (es) Compuestos derivados de indol, antagonistas iap; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de cancer.
EA201070544A1 (ru) Новый класс терапевтических веществ, усиливающих диффузию низкомолекулярных соединений
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
CL2008003593A1 (es) Compuestos derivados de isoxazolo-piridazina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de trastornos cognitivos como el alzheimer
BRPI0605921B8 (pt) compostos orgânicos, seus métodos de preparo e uso, bem como composições farmacêuticas
CL2008002049A1 (es) Compuestos derivados de aminoindol macrociclicos; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
EA201001288A1 (ru) Лечение гипертонии 25-гидроксивитамином d3
EA201071038A1 (ru) Производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40
UY29069A1 (es) Uso de compuestos tpo miméticos y composiciones farmacéuticas para el tratamiento de la anemia
EA200700976A1 (ru) Соединения в виде молекул-конъюгатов, обладающих повышенной активностью в отношении включения клеткой
CL2007002689A1 (es) Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
BRPI0908635B8 (pt) composto e/ou um sal farmaceuticamente aceitável do mesmo e composição farmacêutica
UY28917A1 (es) Derivados de tetrahidroisoquinolilsulfonamidas composiciones farmaceuticas y su uso terapeutico
EA200700403A1 (ru) ТРИЦИКЛИЧЕСКИЕ δ-ОПИОИДНЫЕ МОДУЛЯТОРЫ
CY1109537T1 (el) Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης